BRPI0510963A - derivados pirimidina para o tratamento do crescimento anormal de células - Google Patents

derivados pirimidina para o tratamento do crescimento anormal de células

Info

Publication number
BRPI0510963A
BRPI0510963A BRPI0510963-9A BRPI0510963A BRPI0510963A BR PI0510963 A BRPI0510963 A BR PI0510963A BR PI0510963 A BRPI0510963 A BR PI0510963A BR PI0510963 A BRPI0510963 A BR PI0510963A
Authority
BR
Brazil
Prior art keywords
cell growth
abnormal cell
treatment
pyrimidine derivatives
mammals
Prior art date
Application number
BRPI0510963-9A
Other languages
English (en)
Inventor
John Charles Kath
Michael Joseph Luzzio
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of BRPI0510963A publication Critical patent/BRPI0510963A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

DERIVADOS PIRIMIDINA PARA O TRATAMENTO DO CRESCIMENTO ANORMAL DE CéLULAS A presente invenção está relacionada a um composto de fórmula (1) onde R¬ 1¬-R¬ 4¬ e Ar são como definidos aqui. Tais derivados pirimidina são úteis no tratamento do crescimento anormal de células, tais como o câncer em mamíferos. Essa invenção também está relacionada a um método de utilização de tais compostos no tratamento do crescimento anormal de células em mamíferos, especialmente humanos, e a composições farmacêuticas contendo tais compostos.
BRPI0510963-9A 2004-05-14 2005-05-02 derivados pirimidina para o tratamento do crescimento anormal de células BRPI0510963A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US57120904P 2004-05-14 2004-05-14
PCT/IB2005/001291 WO2005111016A1 (en) 2004-05-14 2005-05-02 Pyrimidine derivatives for the treatment of abnormal cell growth

Publications (1)

Publication Number Publication Date
BRPI0510963A true BRPI0510963A (pt) 2007-11-20

Family

ID=34967760

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0510963-9A BRPI0510963A (pt) 2004-05-14 2005-05-02 derivados pirimidina para o tratamento do crescimento anormal de células

Country Status (9)

Country Link
US (1) US7235562B2 (pt)
EP (1) EP1758887A1 (pt)
JP (1) JP2007537238A (pt)
AR (1) AR049424A1 (pt)
BR (1) BRPI0510963A (pt)
CA (1) CA2564199A1 (pt)
MX (1) MXPA06013165A (pt)
TW (1) TW200612949A (pt)
WO (1) WO2005111016A1 (pt)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0011903D0 (en) * 2000-05-18 2000-07-05 Astrazeneca Ab Combination chemotherapy
CA2529611C (en) * 2002-12-20 2009-12-15 Pfizer Products Inc. Pyrimidine derivatives for the treatment of abnormal cell growth
US20060205945A1 (en) * 2004-05-14 2006-09-14 Pfizer Inc Pyrimidine derivatives for the treatment of abnormal cell growth
US7754714B2 (en) * 2004-05-18 2010-07-13 Rigel Pharmaceuticals, Inc. Cycloalkyl substituted pyrimidinediamine compounds and their uses
WO2007063384A2 (en) * 2005-12-01 2007-06-07 Pfizer Products Inc. Pyrimidine derivatives for the treatment of abnormal cell growth
CA2634646C (en) 2005-12-21 2012-04-10 Pfizer Products Inc. Pyrimidine derivatives for the treatment of abnormal cell growth
US8153791B2 (en) * 2005-12-21 2012-04-10 Janssen Pharmaceutica N.V. Substituted pyrimidinyl oxime kinase inhibitors
WO2007081966A2 (en) * 2006-01-09 2007-07-19 University Of Southern California Small molecules for treating cancer and abnormal cell proliferation disorders
US8013153B2 (en) * 2006-03-23 2011-09-06 Janssen Pharmaceutica, N.V. Substituted pyrimidine kinase inhibitors
ES2555803T3 (es) 2006-10-23 2016-01-08 Cephalon, Inc. Fusión de derivados bicíclicos 2,4-diaminopirimidina como utilizar inhibidores ALK y c-Met
US8168662B1 (en) 2006-11-06 2012-05-01 Poniard Pharmaceuticals, Inc. Use of picoplatin to treat colorectal cancer
US8178564B2 (en) * 2006-11-06 2012-05-15 Poniard Pharmaceuticals, Inc. Use of picoplatin to treat colorectal cancer
US8168661B2 (en) * 2006-11-06 2012-05-01 Poniard Pharmaceuticals, Inc. Use of picoplatin to treat colorectal cancer
US8173686B2 (en) 2006-11-06 2012-05-08 Poniard Pharmaceuticals, Inc. Use of picoplatin to treat colorectal cancer
US20110033528A1 (en) * 2009-08-05 2011-02-10 Poniard Pharmaceuticals, Inc. Stabilized picoplatin oral dosage form
CN101678215B (zh) 2007-04-18 2014-10-01 辉瑞产品公司 用于治疗异常细胞生长的磺酰胺衍生物
KR101294731B1 (ko) * 2007-06-04 2013-08-16 삼성디스플레이 주식회사 어레이 기판, 이를 갖는 표시패널 및 이의 제조방법
US20100260832A1 (en) * 2007-06-27 2010-10-14 Poniard Pharmaceuticals, Inc. Combination therapy for ovarian cancer
TW200916094A (en) * 2007-06-27 2009-04-16 Poniard Pharmaceuticals Inc Stabilized picoplatin dosage form
US20100310661A1 (en) * 2007-07-16 2010-12-09 Poniard Pharmaceuticals, Inc. Oral formulations for picoplatin
CA2715348A1 (en) * 2008-02-08 2009-08-13 Poniard Pharmaceuticals, Inc. Use of picoplatin and bevacizumab to treat colorectal cancer
MX2010010968A (es) * 2008-04-07 2010-10-26 Irm Llc Compuestos y composiciones como inhibidores de cinasa de proteina.
US8927547B2 (en) 2010-05-21 2015-01-06 Noviga Research Ab Pyrimidine derivatives
ES2577829T3 (es) 2010-06-04 2016-07-19 F. Hoffmann-La Roche Ag Derivados de aminopirimidina como moduladores de la LRRK2
US9526648B2 (en) 2010-06-13 2016-12-27 Synerz Medical, Inc. Intragastric device for treating obesity
US10420665B2 (en) 2010-06-13 2019-09-24 W. L. Gore & Associates, Inc. Intragastric device for treating obesity
US8628554B2 (en) 2010-06-13 2014-01-14 Virender K. Sharma Intragastric device for treating obesity
US10010439B2 (en) 2010-06-13 2018-07-03 Synerz Medical, Inc. Intragastric device for treating obesity
US20120244141A1 (en) 2010-09-28 2012-09-27 Boehringer Ingelheim International Gmbh Stratification of cancer patients for susceptibility to therapy with PTK2 inhibitors
NO2638031T3 (pt) 2010-11-10 2018-03-10
DK2688883T3 (en) 2011-03-24 2016-09-05 Noviga Res Ab pyrimidine
JP6118808B2 (ja) * 2011-10-31 2017-04-19 ザ メソジスト ホスピタル リサーチ インスティテュート ヒトグリオームを治療するためのｍａｏ標的化／探索部分を含む化合物
KR102012057B1 (ko) * 2011-11-29 2019-08-19 제넨테크, 인크. Lrrk2 조절제로서 아미노피리미딘 유도체
US10300058B2 (en) 2014-04-18 2019-05-28 Xuanzhu Pharma Co., Ltd. Tyrosine kinase inhibitor and uses thereof
EP3371154A4 (en) 2015-10-30 2019-06-05 Trillium Therapeutics Inc. HETEROCYCLIC DERIVATIVES AND THEIR USE FOR THE TREATMENT OF CNS DISORDERS
US10779980B2 (en) 2016-04-27 2020-09-22 Synerz Medical, Inc. Intragastric device for treating obesity
WO2019043208A1 (en) 2017-09-04 2019-03-07 F. Hoffmann-La Roche Ag DIHYDROQUINOLINONES
KR102709127B1 (ko) * 2018-12-27 2024-09-24 하이노바 파마슈티컬스 인코포레이티드 Fak 억제제 및 그 약물 조합물
KR20220153582A (ko) 2020-02-14 2022-11-18 솔크 인스티튜트 포 바이올로지칼 스터디즈 마크로시클릭 ulk1/2 억제제
KR20220154094A (ko) * 2020-02-14 2022-11-21 솔크 인스티튜트 포 바이올로지칼 스터디즈 Ulk1/2 억제제를 이용한 단일 및 병용 요법
CN116854687B (zh) * 2021-03-23 2025-07-25 杭州阿诺生物医药科技有限公司 Hpk1激酶抑制剂化合物
TW202304434A (zh) * 2021-04-08 2023-02-01 大陸商杭州阿諾生物醫藥科技有限公司 一種高活性的ｈｐｋ１激酶抑制劑

Family Cites Families (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US171359A (en) * 1875-12-21 Improvement in bearings for journals
US162802A (en) * 1875-05-04 Improvement in light-house lanterns
US181A (en) * 1837-04-25 Bodkin fob inserting corset or other grooved rings into cloth or canvas
US4507146A (en) * 1982-12-28 1985-03-26 Ciba-Geigy Corporation 2,4-Diamino-6-halo-5-trifluoromethylpyrimidines having herbicidal activity
US4864021A (en) * 1984-10-30 1989-09-05 Otsuka Pharmaceutical Co., Ltd. 5-fluorouracil derivatives
US4983608A (en) * 1989-09-05 1991-01-08 Hoechst-Roussell Pharmaceuticals, Inc. N-substituted-4-pyrimidinamines and pyrimidinediamines
DE4029650A1 (de) 1990-09-19 1992-03-26 Hoechst Ag 2-anilino-pyrimidine, verfahren zu ihrer herstellung, sie enthaltene mittel und ihre verwendung als fungizide
AU2954992A (en) 1991-11-13 1993-06-15 Mta Kozponti Kemiai Kutato Intezete Process for preparing n-(arylsulphonyl)-carbamide acid derivates and intermediates useful for carrying out this process
DE4137291A1 (de) 1991-11-13 1993-05-19 Bayer Ag Verfahren zur kontinuierlichen umsetzung von halogenpyrimidinen mit aminen
FR2686339B1 (fr) 1992-01-22 1994-03-11 Adir Cie Nouveaux amides et sulfonamides naphtaleniques, leurs procedes de preparation et les compositions pharmaceutiques qui les contiennent.
US5521184A (en) * 1992-04-03 1996-05-28 Ciba-Geigy Corporation Pyrimidine derivatives and processes for the preparation thereof
EP0642502B1 (en) 1992-05-22 2000-07-12 E.I. Du Pont De Nemours And Company Fungicidal imidazolinones
JP3071830B2 (ja) 1995-10-02 2000-07-31 エフ・ホフマン−ラ ロシュ アーゲー ５ｈｔ２ｃ受容体アンタゴニストとしてのピリミジン誘導体
GB9523675D0 (en) 1995-11-20 1996-01-24 Celltech Therapeutics Ltd Chemical compounds
TW440563B (en) * 1996-05-23 2001-06-16 Hoffmann La Roche Aryl pyrimidine derivatives and a pharmaceutical composition thereof
BR9710808A (pt) 1996-08-06 1999-08-17 Pfizer Derivados biciclicos 6,6 ou 6,7 contendo pirito ou pirimido substitu¡dos
EA002113B1 (ru) 1996-09-04 2001-12-24 Пфайзер Инк. Производные индазола и их использование в качестве ингибиторов фосфодиэстеразы (фдэ) типа iv и продуцирования фактора некроза опухоли (фно)
GB2338957B (en) 1997-02-19 2001-08-01 Berlex Lab N-heterocyclic derivatives as nos inhibitors
TW436485B (en) 1997-08-01 2001-05-28 American Cyanamid Co Substituted quinazoline derivatives
EA200000840A1 (ru) 1998-02-17 2001-02-26 Туларик, Инк. Антивирусные производные пиримидина
ATE342892T1 (de) 1998-08-29 2006-11-15 Astrazeneca Ab Pyrimidine verbindungen
US6297258B1 (en) * 1998-09-29 2001-10-02 American Cyanamid Company Substituted 3-cyanoquinolines
IL142092A0 (en) 1998-09-29 2002-03-10 American Cyanamid Co Substituted 3-cyanoquinolines as protein tyrosine kinases inhibitors
GB9828511D0 (en) 1998-12-24 1999-02-17 Zeneca Ltd Chemical compounds
GB9922171D0 (en) 1999-09-21 1999-11-17 Zeneca Ltd Chemical compounds
GB9924862D0 (en) * 1999-10-20 1999-12-22 Celltech Therapeutics Ltd Chemical compounds
AU3704101A (en) 2000-02-17 2001-08-27 Amgen Inc Kinase inhibitors
GB0004887D0 (en) * 2000-03-01 2000-04-19 Astrazeneca Uk Ltd Chemical compounds
CN1190197C (zh) 2000-03-13 2005-02-23 惠氏控股公司 氰基喹啉用于制备治疗或抑制结肠息肉药物中的用途
US6525051B2 (en) 2000-03-27 2003-02-25 Schering Aktiengesellschaft N-heterocyclic derivatives as NOS inhibitors
EP1363888A2 (en) 2000-07-07 2003-11-26 Cancer Research Technology Limited Therapeutic acridone and acridine compounds
WO2002012228A1 (en) 2000-08-09 2002-02-14 Astrazeneca Ab Cinnoline compounds
AU2001277621A1 (en) 2000-08-09 2002-03-04 Astrazeneca Ab Antiangiogenic bicyclic derivatives
WO2002012227A2 (en) 2000-08-09 2002-02-14 Astrazeneca Ab Indole, azaindole and indazole derivatives having vegf inhibiting activity
WO2002016352A1 (en) 2000-08-21 2002-02-28 Astrazeneca Ab Quinazoline derivatives
JO2654B1 (en) 2000-09-04 2012-06-17 شركة جانسين فارماسوتيكا ان. في Multiple aryl caroxa amides are useful as lipid - lowering agents
BR0116452A (pt) 2000-12-21 2003-09-30 Glaxo Group Ltd Composto, composição farmacêutica, uso de um composto
BR0209774A (pt) 2001-05-29 2004-06-01 Schering Ag Pirimidinas inibidoras de cdk, sua preparação e aplicação como medicamento
GB0113041D0 (en) 2001-05-30 2001-07-18 Astrazeneca Ab Chemical compounds
CA2450934A1 (en) * 2001-06-19 2002-12-27 Marco Dodier Pyrimidine inhibitors of phosphodiesterase (pde) 7
US6939874B2 (en) 2001-08-22 2005-09-06 Amgen Inc. Substituted pyrimidinyl derivatives and methods of use
US6927293B2 (en) * 2001-08-30 2005-08-09 Merck & Co., Inc. Tyrosine kinase inhibitors
WO2003030909A1 (en) * 2001-09-25 2003-04-17 Bayer Pharmaceuticals Corporation 2- and 4-aminopyrimidines n-substtituded by a bicyclic ring for use as kinase inhibitors in the treatment of cancer
ATE407678T1 (de) * 2001-10-17 2008-09-15 Boehringer Ingelheim Pharma Pyrimidinderivate, arzneimittel enthaltend diese verbindungen, deren verwendung und verfahren zu ihrer herstellung
TWI329105B (en) 2002-02-01 2010-08-21 Rigel Pharmaceuticals Inc 2,4-pyrimidinediamine compounds and their uses
BR0307375A (pt) 2002-02-05 2004-12-07 Wyeth Corp Processo para a sìntese de ácidos n-acil-2-amino-4-alcóxi-5-nitro-benzóicos
GB0206215D0 (en) 2002-03-15 2002-05-01 Novartis Ag Organic compounds
WO2003095448A1 (en) 2002-05-06 2003-11-20 Bayer Pharmaceuticals Corporation Pyridinyl amino pyrimidine derivatives useful for treating hyper-proliferative disorders
UA80767C2 (en) * 2002-12-20 2007-10-25 Pfizer Prod Inc Pyrimidine derivatives for the treatment of abnormal cell growth
CA2529611C (en) * 2002-12-20 2009-12-15 Pfizer Products Inc. Pyrimidine derivatives for the treatment of abnormal cell growth

Also Published As

Publication number Publication date
EP1758887A1 (en) 2007-03-07
US7235562B2 (en) 2007-06-26
TW200612949A (en) 2006-05-01
US20050256111A1 (en) 2005-11-17
WO2005111016A1 (en) 2005-11-24
AR049424A1 (es) 2006-08-02
CA2564199A1 (en) 2005-11-24
JP2007537238A (ja) 2007-12-20
MXPA06013165A (es) 2007-02-13

Similar Documents

Publication Publication Date Title
BRPI0510963A (pt) derivados pirimidina para o tratamento do crescimento anormal de células
BRPI0510980A (pt) derivados de pirimidina para o tratamento do crescimento anormal de células
BRPI0511132A (pt) derivados de pirimidina e composição farmacêutica compreendendo os mesmos
TNSN06074A1 (en) Pyrimidine derivatives for the treatment of abnormal cell growth
MX2009011090A (es) Derivados de sulfonil amida para el tratamiento del crecimiento celular anormal.
UA89123C2 (ru) Производные пиримидина для лечения абнормального роста клеток
EA200971104A1 (ru) Производные бензимидазола
TW200720268A (en) 1h-benzimidazole-4-carboxamides substituted with a quaternary carbon at the 2-position are potent PARP inhibitors
CO5640039A2 (es) Compuesto de pirazol-amida sustituidos utiles como inhibidores de cinasa
NO20061194L (no) Mitotiske kinesininbibitorer
TW200736229A (en) Substituted 1H-benzimidazole-4-carboxamides are potent PARP inhibitors
EA201100874A1 (ru) Соединения для лечения рака
BRPI0511138A (pt) derivados de pirimidina para o tratamento de desenvolvimento celular anormal
TW200720232A (en) Crystalline solid forms of tigecycline and methods of preparing same
BRPI0713381A2 (pt) composto, composição farmacêutica, e, método para o tratamento de uma doença
ATE543803T1 (de) 3-ä2-(3-azylamino-2-oxo-2h-pyridin-1- yl)acetylaminoü-4-oxopentansäurederivate und deren verwendung als caspase-inhibitoren
WO2007076087A3 (en) 3-aryl-substituted quinazolones, and uses thereof
MX2009012079A (es) Compuestos heterociclicos condensados como inhibidores de proteina cinasas.
UA93313C2 (en) Benzimidazole derivatives
WO2006119402A3 (en) C-linked glucoronide of n-(4-hydroxybenzyl) retinone, analogs thereof, and method of using the same to inhibit neoplastic cell growth
CU20060216A7 (es) Derivados de pirimidina para tratar el crecimiento celular anómalo
DOP2005000086A (es) Derivados de pirimidina para tratar el crecimiento celular anomalo
TH81167A (th) อนุพันธ์ไพริมิดีนเพื่อการรักษาการเจริญเติบโตผิดปกติของเซล
GB0402101D0 (en) Organic compounds
CU20080126A7 (es) Derivados de pirimidina para el tratamiento del crecimiento celular anormal

Legal Events

Date Code Title Description
B08F Application fees: application dismissed [chapter 8.6 patent gazette]

Free format text: REFERENTE A 5A E 6 ANUIDADE(S).

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE A 8.6 NA RPI 2099 DE 29/03/2011.